A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Clinical trial NCT03002103 · SUSPENDED

Trial details

NCT number: NCT03002103
Sponsor: SynCore Biotechnology Co., Ltd.
Status: SUSPENDED
Phase: Phase 3
Study type: INTERVENTIONAL

Triple-Negative Breast Cancer

Start date: 2016-11-23
Primary completion: 2025-03-01
Enrollment: 420

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.